Background: Endocrine Orbitopathy (EO) is the most frequent and important extrathyroidal stigma of Graves' disease. In the active stage of the orbitopathy fibrosis and hypertrophy of the extra-ocular muscles can lead to visual impairment and diplopia. In the stable phase of the disease surgical treatment by orbital expansion and/or orbital decompression can improve the quality of life and it is indicated for morpho-aesthetic and functional reasons.
Methods: From 1998 to 2009 a consecutive series of 131 patients (251 orbits) with endocrine orbitopathy underwent surgery by different techniques. The medical records of 102 patients (78%) and 196 orbits were available to be assessed retrospectively. Ninety-four patients had bilateral involvement of the orbits and eight unilateral. A total of 556 operations were performed.
Results: Mean pre-operative exophthalmos was 24.7 ± 2.5 mm (max-min 20-34), mean post-operative exophthalmos was 21 ± 1.8 mm (max-min 18-26), and mean differential exophthalmos was 3.9 ± 1.7 mm (max-min 1-9). The reduction in exophthalmos after surgery had a mean value of 3.8 mm (min 1, max 9). Kaplan Meier algorithm demonstrates that intra-operative cortisone injection had an adverse effect on post-operative diplopia.
Conclusions: The surgical technique used should be adapted to the individual patients' needs. In severe cases intraorbital fat removal and bony decompression can be and carried out in one surgical procedure. An integrated global approach by a multidisciplinary team is strongly recommended. Strabismus surgery is a significant part of the overall treatment. The Authors suggest general surgical guidelines and an algorithm of treatment in EO.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jcms.2011.05.014 | DOI Listing |
Vestn Oftalmol
December 2024
Russian Medical Academy of Continuous Professional Education, Moscow, Russia.
Endocrine ophthalmopathy (EO; also called Graves' ophthalmopathy, thyroid eye disease) is a common extrathyroidal manifestation of Graves' disease, characterized by the presence of autoimmune inflammatory process in the orbital soft tissues. The prevalence of EO is approximately 10 cases per 10.000 population, higher in individuals over 50 years old.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
December 2024
Department of Ophthalmology, The Second Affiliated Hospital of Chengdu Medical College, Nuclear Industry 416 Hospital, Chengdu, Sichuan, China.
Objective: The aim of this study was to compare the diagnostic performance of T2 mapping and Dixon in thyroid-associated ophthalmopathy's disease activity.
Methods: Published studies were collected by systematically searching the databases PubMed, Embase, Cochrane Library, Google Scholar, Medline, Web of Science, CNKI, VIP, and WANFANG. The sensitivities, specificities, likelihood ratios, and diagnostic odds ratio (DOR) were confirmed.
BMJ Open Ophthalmol
December 2024
Ophthalmology, National Yang Ming Chiao Tung University - Yangming Campus, Taipei, Taiwan
Aim: There remain limited therapies to treat thyroid eye disease (TED) orbital fibrosis, highlighting the urgency to develop novel targets. Transforming growth factor-β1 (TGF-β1)-induced myofibroblast transdifferentiation from orbital fibroblasts are important pathogenetic factor of TED. Endoplasmic reticulum (ER) stress may play a role in TED pathogenesis since it has been linked to liver, kidney, heart and lung fibrotic remodelling.
View Article and Find Full Text PDFBMC Endocr Disord
December 2024
Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Purpose: To evaluate the utility of apparent diffusion coefficient (ADC) values of extraocular muscles (EOMs) in differentiating activity of thyroid eye disease (TED).
Method: Forty-two TED patients who underwent diffusion tensor imaging(DTI) were retrospectively enrolled in this study, including 29 patients in analysis group and 13 patients in validation group. The mean, maximum and minimum ADC value of each EOM were regarded as ADCmean, ADCmax and ADCmin.
J Clin Endocrinol Metab
December 2024
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Context: Thyroid stimulating immunoglobulin (TSI) and thyrotropin receptor antibody (TRAb) are specific biomarkers for Graves' disease (GD), but their clinical characteristics are not fully understood.
Objectives: To clarify the clinical features and prognostic significance of TSI and TRAb in patients with GD.
Design: A retrospective data analysis and a follow-up study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!